What is Cell Applications?
Cell Applications, Inc. has been a global leader in the isolation, purification, and culture of primary cells since 1994. The company specializes in providing physiologically relevant, high-quality primary cells cultured in optimized, cell type-specific media. Renowned for its strong foundations of high cell purity, rigorous quality control, and comprehensive characterization, Cell Applications offers a primary cell toolbox including stem cells, differentiation products, tissue engineering solutions, and three-dimensional cell models. These are supported by specialized media, culture reagents, growth factors, transfection reagents, antibodies, and RNA products. Cell Applications also provides custom services and products supporting basic life science research at universities and research institutes, as well as drug discovery and development programs at major pharmaceutical companies. Their operations adhere to FDA 21 CFR Part 820 compliant manufacturing standards with cGMP approval.
How much funding has Cell Applications raised?
Cell Applications has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Cell Applications
PPP
Public-Private Partnership
What's next for Cell Applications?
The company's large-scale late-stage funding context suggests a focus on scaling operations, expanding market reach, and potentially further developing its advanced cell culture technologies and custom service offerings. This strategic investment is likely to fuel continued innovation in areas such as tissue engineering, spheroid generation, and protocol development, reinforcing Cell Applications' role in supporting critical research and drug discovery initiatives worldwide. The company's commitment to providing highly characterized cell products and comprehensive technical support, backed by cGMP manufacturing, positions it for sustained growth and impact in the competitive biotechnology landscape.
See full Cell Applications company page
